Nirat Beohar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nirat Beohar has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
Charles J. Davidson
7 shared publicationsJames D. Flaherty
§Feinberg School of Medicine, Northwestern University, Chicago, Illinois
5 shared publicationsRobert O. Bonow
§Feinberg School of Medicine, Northwestern University, Chicago, Illinois
5 shared publicationsSheridan N. Meyers
Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
4 shared publications- Daniel C. Lee
Department of Radiology, Northwestern University Feinberg School of Medicine, 737 N Michigan Ave, Ste 1600, Chicago, IL 60611
3 shared publications Karen Pieper
Duke Clinical Research Institute, Duke University, Durham, North Carolina
3 shared publications
Latest Publications
- 1 April 2011
- Published by Elsevier in American Heart Journal
- Vol. 161 (4) , 755-763
The impact of race/ethnicity on baseline characteristics and the burden of coronary atherosclerosis in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial
- 1 April 2011
- Published by Elsevier in American Heart Journal
- Vol. 161 (4) , 755-763
The impact of race/ethnicity on baseline characteristics and the burden of coronary atherosclerosis in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial
- 23 August 2010
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 23 (6) , 528-545
Off‐Label Use of Drug‐Eluting versus Bare Metal Stents: A Lesion‐Specific Systematic Review of Long‐Term Outcomes
Objective: The purpose of this systematic review was to evaluate differences in lesion‐specific outcomes with the “off‐label” use of drug‐eluting stents (DES) versus bare metal stents (BMS). Methods: MEDLINE, PubMed, the Cochrane databases, and other Web were searched for studies evaluating off‐label use of DES and BMS with the same characteristics. Of 1,258 abstracts or manuscripts reviewed, 112 studies were included (total N = 23,438). Studies were excluded if patients received both types of stent or no stent; lesion type was unknown; lesion‐specific outcomes for ≥6 months were unavailable; or Results: Overall mortality at 6–12 months was approximately 3% for BMS and DES for off‐label use. Increase in mortality was greater from 6–12 months to 2 years with BMS than with DES (3.3%–9.1%; 2.8%–4.1%); however, rates were similar at 3 years (BMS: 18.8%; DES:15.3%). Myocardial Infarction rates were similar for both types at 6–12 months (BMS: 6.5%; DES: 6.0%). Overall rates of stent thrombosis were 1.8% and 1.7% for BMS and DES, respectively. Similar or slightly lower rates of stent thrombosis were seen for most lesion types, except higher rates for small vessels for BMS (5.2%) and true bifurcation for DES (3.3%). Rates of target lesion revascularization (TLR) were 7.5% for BMS and 19.6% for DES at 6–12 months. At 2‐years TLR remained lower than DES. When the combined group was compared to registry data alone, similar values were seen. Conclusions: Rates of mortality, myocardial infarction (MI), and stent thrombosis were similar in patients receiving BMS or DES, while TLR rates were lower in DES patients. (J Interven Cardiol 2010;23:528–545)
- 23 August 2010
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 23 (6) , 528-545
Off‐Label Use of Drug‐Eluting versus Bare Metal Stents: A Lesion‐Specific Systematic Review of Long‐Term Outcomes
Objective: The purpose of this systematic review was to evaluate differences in lesion‐specific outcomes with the “off‐label” use of drug‐eluting stents (DES) versus bare metal stents (BMS). Methods: MEDLINE, PubMed, the Cochrane databases, and other Web were searched for studies evaluating off‐label use of DES and BMS with the same characteristics. Of 1,258 abstracts or manuscripts reviewed, 112 studies were included (total N = 23,438). Studies were excluded if patients received both types of stent or no stent; lesion type was unknown; lesion‐specific outcomes for ≥6 months were unavailable; or Results: Overall mortality at 6–12 months was approximately 3% for BMS and DES for off‐label use. Increase in mortality was greater from 6–12 months to 2 years with BMS than with DES (3.3%–9.1%; 2.8%–4.1%); however, rates were similar at 3 years (BMS: 18.8%; DES:15.3%). Myocardial Infarction rates were similar for both types at 6–12 months (BMS: 6.5%; DES: 6.0%). Overall rates of stent thrombosis were 1.8% and 1.7% for BMS and DES, respectively. Similar or slightly lower rates of stent thrombosis were seen for most lesion types, except higher rates for small vessels for BMS (5.2%) and true bifurcation for DES (3.3%). Rates of target lesion revascularization (TLR) were 7.5% for BMS and 19.6% for DES at 6–12 months. At 2‐years TLR remained lower than DES. When the combined group was compared to registry data alone, similar values were seen. Conclusions: Rates of mortality, myocardial infarction (MI), and stent thrombosis were similar in patients receiving BMS or DES, while TLR rates were lower in DES patients. (J Interven Cardiol 2010;23:528–545)
- 1 June 2010
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 3 (6) , 602-611
Drug-Eluting Versus Bare-Metal Stents in Unprotected Left Main Coronary Artery Stenosis
- 1 June 2010
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 3 (6) , 602-611
Drug-Eluting Versus Bare-Metal Stents in Unprotected Left Main Coronary Artery Stenosis
- 30 April 2009
- Published by Elsevier in Academic Radiology
- Vol. 16 (4) , 412-417
Detection of Stent Fractures: A Comparison of 64-slice CT, Conventional Cine-angiography, and Intravascular Ultrasonography
- 30 April 2009
- Published by Elsevier in Academic Radiology
- Vol. 16 (4) , 412-417
Detection of Stent Fractures: A Comparison of 64-slice CT, Conventional Cine-angiography, and Intravascular Ultrasonography
- Open Access
- 9 May 2007
- Published by American Medical Association (AMA) in JAMA
- Vol. 297 (18) , 1992-2000
Outcomes and Complications Associated With Off-Label and Untested Use of Drug-Eluting Stents
Research from JAMA — Outcomes and Complications Associated With Off-Label and Untested Use of Drug-Eluting Stents — ContextLimited data exist regarding use of drug-eluting stents outside of approved indications in real-world settings.ObjectivesTo determine the frequency, safety, and effectiveness of drug-eluting stents for off-label (restenosis, bypass graft lesion, long lesions, vessel size outside of information for use recommendation) and untested (left main, ostial, bifurcation, or total occlusion lesions) indications in percutaneous coronary intervention (PCI).Design, Setting, and PatientsObservational, prospective, multicenter registry to evaluate in-hospital, 30-day, and 1-year outcomes among patients undergoing PCI between January and June 2005 in 140 US academic and community medical centers. Of 7752 PCI-treated patients, 6993 (90%) received drug-eluting stents; of these, 5851 (84%) received no other devices. Standard, off-label, and untested use was determined in 5541 (95%) of these 5851 patients, constituting the study cohort.Main Outcome MeasuresFrequency of off-label and untested use, 1-year repeat target vessel revascularization, and composite of death, myocardial infarction (MI), or stent thrombosis at in-hospital follow-up and during 1 year of follow-up.ResultsOf 5541 patients receiving drug-eluting stents, 2588 (47%) received stents for off-label or untested indications. Adjusted in-hospital risk of death, MI, or stent thrombosis was not statistically different with off-label or untested vs standard use. At 30 days, the risk of this composite end point was significantly higher with off-label use (adjusted hazard ratio [HR], 2.08; 95% confidence interval [CI], 1.24-3.48; P = .005) but not untested use (adjusted HR, 1.45; 95% CI, 0.79-2.67; P = .23). Excluding early events, this end point was not different at 1 year with off-label use (adjusted HR, 1.10; 95% CI, 0.79-1.54; P = .57) or untested use (adjusted HR, 0.91; 95% CI, 0.60-1.38; P = .66). At 1 year, compared with standard use, significantly higher rates of target vessel revascularization were associated with off-label use (adjusted HR, 1.49; 95% CI, 1.13-1.98; P = .005) and untested use (adjusted HR, 1.49; 95% CI, 1.10-2.02; P = .01), although absolute rates were low (standard, 4.4% [n = 113]; off-label, 7.6% [n = 95]; untested, 6.7% [n = 72]).ConclusionsIn contemporary US practice, off-label and untested use of drug-eluting stents is common. Compared with standard use, relative early safety is lower with off-label use, and the long-term effectiveness is lower with both off-label and untested use. However, the absolute event rates remain low.
- 9 May 2007
- Published by American Medical Association (AMA) in JAMA
- Vol. 297 (18) , 1992-2000
Open AccessOutcomes and Complications Associated With Off-Label and Untested Use of Drug-Eluting Stents
Research from JAMA — Outcomes and Complications Associated With Off-Label and Untested Use of Drug-Eluting Stents — ContextLimited data exist regarding use of drug-eluting stents outside of approved indications in real-world settings.ObjectivesTo determine the frequency, safety, and effectiveness of drug-eluting stents for off-label (restenosis, bypass graft lesion, long lesions, vessel size outside of information for use recommendation) and untested (left main, ostial, bifurcation, or total occlusion lesions) indications in percutaneous coronary intervention (PCI).Design, Setting, and PatientsObservational, prospective, multicenter registry to evaluate in-hospital, 30-day, and 1-year outcomes among patients undergoing PCI between January and June 2005 in 140 US academic and community medical centers. Of 7752 PCI-treated patients, 6993 (90%) received drug-eluting stents; of these, 5851 (84%) received no other devices. Standard, off-label, and untested use was determined in 5541 (95%) of these 5851 patients, constituting the study cohort.Main Outcome MeasuresFrequency of off-label and untested use, 1-year repeat target vessel revascularization, and composite of death, myocardial infarction (MI), or stent thrombosis at in-hospital follow-up and during 1 year of follow-up.ResultsOf 5541 patients receiving drug-eluting stents, 2588 (47%) received stents for off-label or untested indications. Adjusted in-hospital risk of death, MI, or stent thrombosis was not statistically different with off-label or untested vs standard use. At 30 days, the risk of this composite end point was significantly higher with off-label use (adjusted hazard ratio [HR], 2.08; 95% confidence interval [CI], 1.24-3.48; P = .005) but not untested use (adjusted HR, 1.45; 95% CI, 0.79-2.67; P = .23). Excluding early events, this end point was not different at 1 year with off-label use (adjusted HR, 1.10; 95% CI, 0.79-1.54; P = .57) or untested use (adjusted HR, 0.91; 95% CI, 0.60-1.38; P = .66). At 1 year, compared with standard use, significantly higher rates of target vessel revascularization were associated with off-label use (adjusted HR, 1.49; 95% CI, 1.13-1.98; P = .005) and untested use (adjusted HR, 1.49; 95% CI, 1.10-2.02; P = .01), although absolute rates were low (standard, 4.4% [n = 113]; off-label, 7.6% [n = 95]; untested, 6.7% [n = 72]).ConclusionsIn contemporary US practice, off-label and untested use of drug-eluting stents is common. Compared with standard use, relative early safety is lower with off-label use, and the long-term effectiveness is lower with both off-label and untested use. However, the absolute event rates remain low.
- 13 March 2007
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 69 (5) , 721-728
Quantitative assessment of regional left ventricular function with cardiac MRI: Three‐dimensional centersurface method
Objectives: The purpose of this study was to provide the first in vivo validation of a three‐dimensional (3D) method to quantify regional left ventricular (LV) function with cardiac magnetic resonance (CMR) imaging after myocardial infarction (MI). Background: Current cardiac methods to analyze LV function are limited by geometric assumptions and observer biases. Methods: MI was induced percutaneously by 90‐min proximal left circumflex artery balloon occlusion in 25 Yucatan minipigs. Cine and contrast‐enhanced (CE) CMR imaging was performed at 5 days (n = 21) and 8 weeks (n = 22) post‐MI. Twelve control animals without MI were also imaged. Regional wall thickening was measured orthogonal to the myocardial wall using the centersurface method. The left ventricle was divided into 16 segments (six basal 60°, six middle 60°, four apical 90°). Normal ranges for segmental wall thickness and wall thickening were defined as mean ± 2D in control hearts. Hypokinesis was defined as a segmental thickening value below the normal range. Results: Hypokinesis following MI was identified in the inferior, inferolateral and anterolateral segments when compared with controls and corresponded to areas of infarction by CE CMR. The aggregate wall thickening was also expressed as a percentage at 5 days (Infarct zone: 15% ± 16% vs. NonInfarct zone 33% ± 20%, P < 0.001) and 8 weeks (Infarct zone 20% ± 20% vs. NonInfarct zone 32% ± 22%, P < 0.001). Conclusions: The centersurface method can quantify regional wall thickening and spatially identify regions of abnormal function in 3D after MI without relying on geometric assumptions. This method may be a valuable tool to quantify regional LV function in the assessment of myocardial viability, ischemia, infarction, and the response to therapeutic interventions.
- 13 March 2007
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 69 (5) , 721-728
Quantitative assessment of regional left ventricular function with cardiac MRI: Three‐dimensional centersurface method
Objectives: The purpose of this study was to provide the first in vivo validation of a three‐dimensional (3D) method to quantify regional left ventricular (LV) function with cardiac magnetic resonance (CMR) imaging after myocardial infarction (MI). Background: Current cardiac methods to analyze LV function are limited by geometric assumptions and observer biases. Methods: MI was induced percutaneously by 90‐min proximal left circumflex artery balloon occlusion in 25 Yucatan minipigs. Cine and contrast‐enhanced (CE) CMR imaging was performed at 5 days (n = 21) and 8 weeks (n = 22) post‐MI. Twelve control animals without MI were also imaged. Regional wall thickening was measured orthogonal to the myocardial wall using the centersurface method. The left ventricle was divided into 16 segments (six basal 60°, six middle 60°, four apical 90°). Normal ranges for segmental wall thickness and wall thickening were defined as mean ± 2D in control hearts. Hypokinesis was defined as a segmental thickening value below the normal range. Results: Hypokinesis following MI was identified in the inferior, inferolateral and anterolateral segments when compared with controls and corresponded to areas of infarction by CE CMR. The aggregate wall thickening was also expressed as a percentage at 5 days (Infarct zone: 15% ± 16% vs. NonInfarct zone 33% ± 20%, P < 0.001) and 8 weeks (Infarct zone 20% ± 20% vs. NonInfarct zone 32% ± 22%, P < 0.001). Conclusions: The centersurface method can quantify regional wall thickening and spatially identify regions of abnormal function in 3D after MI without relying on geometric assumptions. This method may be a valuable tool to quantify regional LV function in the assessment of myocardial viability, ischemia, infarction, and the response to therapeutic interventions.
- 6 January 2004
- Published by Wolters Kluwer Health in Circulation
- Vol. 109 (1) , 108-113
Antirestenotic Effects of a Locally Delivered Caspase Inhibitor in a Balloon Injury Model
Background— The precise role of arterial barotrauma-mediated apoptosis in causing restenosis is unclear. The purpose of this study was to determine if a link exists between angioplasty-mediated medial smooth muscle cell apoptosis and subsequent neointimal hyperplasia. Methods and Results— Bilateral iliac artery angioplasty was performed in 25 male New Zealand White rabbits. Simultaneous with balloon injury, each artery was treated locally with either the caspase inhibitor N -benzyloxycarbonyl-Val-Ala-Asp(Ome)-fluoromethylketone (ZVAD-fmk) or control. In the acute cohort that was survived to 4 hours (n=10, 7 high dose and 3 low dose), an apoptotic index was calculated using the terminal deoxynucleotidyl TUNEL method. In the intermediate cohort that was survived to 2 weeks (n=5), luminal reendothelialization was measured via CD-31 staining. In the chronic cohort that was survived to 4 weeks (n=10), neointimal area was measured. In the acute cohort, there was a 40% reduction in the apoptotic index with high-dose ZVAD-fmk ( P =0.008) and a 33% reduction with low-dose ZVAD-fmk ( P =0.08). At 2 weeks, there was no significant difference in the degree of luminal reendothelialization. However, at 4 weeks, there was a 33% (0.33±0.23 versus 0.22±0.20 mm 2 ) ( P Conclusions— The local delivery of ZVAD-fmk during balloon injury inhibits smooth muscle cell apoptosis. This corresponds to a significant reduction in neointimal proliferation seen at 4 weeks without a significant change in the degree of reendothelialization at 2 weeks.
- 6 January 2004
- Published by Wolters Kluwer Health in Circulation
- Vol. 109 (1) , 108-113
Antirestenotic Effects of a Locally Delivered Caspase Inhibitor in a Balloon Injury Model
Background— The precise role of arterial barotrauma-mediated apoptosis in causing restenosis is unclear. The purpose of this study was to determine if a link exists between angioplasty-mediated medial smooth muscle cell apoptosis and subsequent neointimal hyperplasia. Methods and Results— Bilateral iliac artery angioplasty was performed in 25 male New Zealand White rabbits. Simultaneous with balloon injury, each artery was treated locally with either the caspase inhibitor N -benzyloxycarbonyl-Val-Ala-Asp(Ome)-fluoromethylketone (ZVAD-fmk) or control. In the acute cohort that was survived to 4 hours (n=10, 7 high dose and 3 low dose), an apoptotic index was calculated using the terminal deoxynucleotidyl TUNEL method. In the intermediate cohort that was survived to 2 weeks (n=5), luminal reendothelialization was measured via CD-31 staining. In the chronic cohort that was survived to 4 weeks (n=10), neointimal area was measured. In the acute cohort, there was a 40% reduction in the apoptotic index with high-dose ZVAD-fmk ( P =0.008) and a 33% reduction with low-dose ZVAD-fmk ( P =0.08). At 2 weeks, there was no significant difference in the degree of luminal reendothelialization. However, at 4 weeks, there was a 33% (0.33±0.23 versus 0.22±0.20 mm 2 ) ( P Conclusions— The local delivery of ZVAD-fmk during balloon injury inhibits smooth muscle cell apoptosis. This corresponds to a significant reduction in neointimal proliferation seen at 4 weeks without a significant change in the degree of reendothelialization at 2 weeks.
- 1 February 2003
- Vol. 15 (2) , 68-70
A comparison of arterial closure devices to manual compression in liver transplantation candidates undergoing coronary angiography.
Whether arterial closure devices can be used safely in a coagulopathic population undergoing cardiac catheterization and at high risk for groin complications, such as liver transplant candidates, is unknown. In this prospective, non-randomized consecutive series of 80 liver transplant candidates undergoing coronary angiography, manual compression and arterial closure devices were compared. Ilio-femoral angiography was performed to determine suitability for use of the closure device. Bleeding and vascular complications were recorded along with time to ambulation. Arterial closure devices were used in 31 patients (39%), whereas manual compression was used in 49 patients (50 procedures) (61%). There were no significant differences between the two groups with respect to age, sex, cardiac risk factors, peripheral vascular disease, baseline platelet count or baseline INR. There were 10 total vascular complications out of 50 procedures (20%) in the manual compression group compared to 2 vascular complications out of 31 procedures in the arterial closure device group (6%; p = 0.12). The time to ambulation was significantly less in the group receiving arterial closure devices versus manual compression (4.2 1.8 hours versus 6.6 3.7 hours, respectively; p = 0.0003). In coagulopathic patients at higher risk for groin complications, arterial closure devices can be safely used and decrease time to ambulation compared to manual compression.
- 1 February 2003
- Vol. 15 (2) , 68-70
A comparison of arterial closure devices to manual compression in liver transplantation candidates undergoing coronary angiography.
Whether arterial closure devices can be used safely in a coagulopathic population undergoing cardiac catheterization and at high risk for groin complications, such as liver transplant candidates, is unknown. In this prospective, non-randomized consecutive series of 80 liver transplant candidates undergoing coronary angiography, manual compression and arterial closure devices were compared. Ilio-femoral angiography was performed to determine suitability for use of the closure device. Bleeding and vascular complications were recorded along with time to ambulation. Arterial closure devices were used in 31 patients (39%), whereas manual compression was used in 49 patients (50 procedures) (61%). There were no significant differences between the two groups with respect to age, sex, cardiac risk factors, peripheral vascular disease, baseline platelet count or baseline INR. There were 10 total vascular complications out of 50 procedures (20%) in the manual compression group compared to 2 vascular complications out of 31 procedures in the arterial closure device group (6%; p = 0.12). The time to ambulation was significantly less in the group receiving arterial closure devices versus manual compression (4.2 1.8 hours versus 6.6 3.7 hours, respectively; p = 0.0003). In coagulopathic patients at higher risk for groin complications, arterial closure devices can be safely used and decrease time to ambulation compared to manual compression.